DNA microarray platforms for gene expression profiling were invented relatively recently, and breast cancer has been among the earliest and most intensely studied diseases using this technology. The molecular signatures so identified help reveal the biologic spectrum of breast cancers, provide diagnostic tools as well as prognostic and predictive gene signatures, and may identify new therapeutic targets. Data are best presented in an open access format to facilitate external validation, the most crucial step in identifying robust, reproducible gene signatures suitable for clinical translation. Clinically practical applications derived from full expression profile studies already in use include reduced versions of microarrays representing key discriminatory genes and therapeutic targets, quantitative polymerase chain reaction assays, or immunohistochemical surrogate panels (suitable for application to standard pathology blocks). Prospective trials are now underway to determine the value of such tools for clinical decision making in breast cancer; these efforts may serve as a model for using such approaches in other tumor types. 
INTRODUCTION
Since the introduction of DNA microarray (1, 2) technology in the mid-1990s, breast cancer has probably been the carcinoma most intensively studied by gene expression profiling. DNA microarrays allow researchers to measure the expression of tens of thousands of genes concurrently in one tissue sample. Enormous amounts of data are thereby generated, making microarrays an excellent tool for screening studies, for hypothesis generation, and for elucidating broad patterns of gene expression in health and disease. Over the past decade, there have been increasing numbers of reports describing gene signatures that help to explain the biology of breast cancer and/or have potential clinical value for prognosis, for predicting response to treatment, or for identifying therapeutic targets for drug development. Nevertheless, controversy remains about the validity and reproducibility of the findings, in large part because of the nature of these studies, in which thousands of genes are being assessed on a necessarily much smaller number of specimens (3). Owing to the risk, with this type of data set, of generating false inferences (4), an entire new field of bioinformatics has emerged, and the best data analysis tools to use are currently a matter of intense debate. Stringent study design and data interpretation and, most importantly, validation of results on independent cohorts of patient samples, are required for this technology to advance the clinical management of breast cancer (3). Such studies are now underway.
EXPRESSION PROFILING METHODOLOGY Microarray Platforms Used in Breast Cancer Studies
In breast cancer research to date, the most commonly used platforms for gene expression profiling have been spotted cDNA (1) and oligonucleotide microarrays (5). Each platform yields measurements of mRNAs present in a tumor specimen, and requires highquality total RNA that is best isolated from fresh-frozen tissue. The frozen tumors must be handled carefully and consistently during RNA extraction (6) to optimize the integrity and reliability of data for subsequent exploratory data analysis and to allow biologically relevant statistical inferences to be drawn.
Although several platforms for microarray measurements are in use, a mainstay of publicly available sequence information has been the spotted cDNA microarray. Probes are derived from established cDNA libraries, typically encoding 500 to 2000 nucleotides from the 3 regions of transcripts. The sequences are amplified by polymerase chain reaction, then spotted on the surface of a chemically coated microscope glass slide in an array format. These immobilized cDNA sequence probes will bind to fluorescently labeled complementary sequences of corresponding gene targets present in a biological sample. Hybridization characteristics can be different between probes because of variations in spot size, probe length, and G-C content. As a result, the absolute measurements of staining intensities are not strictly comparable among probe spots and are therefore measured relative to a reference sample RNA pool. To label the genes expressed in tumor samples, the purified RNA sample is first reverse transcribed, incorporating a redfluorescing nucleotide (Cy-5-dUTP), then cohybridized onto the microarray slide along with green fluorescent (Cy-3)-labeled reference RNA. The fluorescent signals are measured by emissions at the appropriate wavelengths, and the digitally scanned images are quantified. The two channel images are superimposed, to give a preliminary visual coloring readout representing the gene expression of each spot (Figure 1a) . In this manner, each sample analyzed can generate in the range of 40,000 data points.
The disadvantages of cDNA microarrays, which include repetitive DNA sequences, poorly characterized genes, and variable a b
Figure 1
Publicly accessible primary microarray data. (a) Raw image data from Reference 31. The detail shows a magnified view of one sector of the array, with 576 hybridized cDNA spots. In total, the array consists of 9216 elements (more recent spotted arrays are higher density, with >42,000 elements). (b) GeneXPlorer allows the user to explore cluster diagrams interactively; in this view, genes whose expression is most closely correlated with ERBB2 are shown, including the neighboring GRB7, which is co-amplified with ERBB2 (left, cell lines; right, breast cancer specimens). hybridization kinetics, can be avoided by using fully defined oligonucleotides that represent unique sequences already mapped to the genome. Defined oligonucleotides, typically 30-to 70-mers, are spotted on glass slides using ink jet technology, and the readouts can be interpreted in a similar fashion as those from cDNA microarrays. Agilenttype arrays [e.g., MammaPrint (7)] and nonproprietary human exonic evidence-based oligonucleotide arrays being printed at several academic centers (http://www.microarray. org/sfgf/heebo.do) are examples currently in widespread use. High-density oligonucleotide microarrays, exemplified by Affymetrix GeneChip ® (5) technology, use photolithography and combinatorial chemistry to enable synthesis of probes on a quartz wafer. Typical Affymetrix chips contain between 10 5 to 10 6 defined probe elements. In contrast to spotted oligonucleotide microarrays, the probes on these ultrahigh-density arrays are 25 nucleotides long, with genes represented by a set of 10-20 pairs of perfect match and mismatch probes. The perfect match probes provide quantitative measurements of fluorescent target sample binding, and the mismatch probes serve as internal controls. These high-density microarrays are more expensive than spotted microarrays and are not readily customizable. Affymetrix GeneChip assays incorporate an amplification step and need less total RNA template from each tumor sample, 1-2 μg compared with 10-20 μg needed for spotted cDNA microarrays. Biostatisticians have also prepared open-source statistical procedures written especially for handling such data (e.g., BioConductor, http://www.bioconductor. org). Alternatively, all the above types of microarrays can be used to measure DNA copy number changes, a technique known as array-based comparative genomic hybridization (aCGH) (8, 9).
The identification of limited sets of key genes within expression signatures has provided a justification for collecting focused expression profiles (dozens to hundreds of genes) through quantitative real-time polymerase chain reaction (qRT-PCR) (10, 11). The most relevant genes of interest are deduced from microarray studies and other previous investigations. Using unique primer pairs specific for each gene, mRNA transcripts are amplified in a fashion that allows a very accurate quantization of expression (Figure 2 ). This methodology is applicable to very small specimens (e.g., fine needle aspirate or core biopsy material) and, with proper primer design and optimization, can be applied to formalin-fixed, paraffin-embedded tissues. The choice of genes to include in the Expression profiling by quantitative real-time polymerase chain reaction (qRT-PCR). (a) Formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue blocks are either sectioned (scroll method) or cored (guided by histology) to obtain a sample dominated by invasive breast cancer tissue. (b) Tissue is deparaffinized, followed by total RNA purification and genomic DNA removal. Approximately 0.5 μg from each sample is enough for 200 qRT-PCR runs. (c) The RNA template is split (e.g., on 96-or 384-well plates) for separate qRT-PCR reactions designed to measure individual genes of interest. In each well, mRNA transcripts are reverse transcribed using gene-specific primers into cDNA. (d ) The purified cDNA template is mixed with optimized gene-specific forward and reverse primers for high-throughput SYBR Green-type qRT-PCR. (e) Expression of each gene is quantified from the incorporation curve. ( f ) Measurements are normalized (e.g., using housekeeper gene controls) and can then be plugged into any of the statistical analysis methods for microarray expression profiles. Unsupervised hierarchical clustering on 26 genes splits 18 breast tumor samples into basal-like and luminal breast cancer subtypes.
assay [e.g., optimized for outcome prediction in a particular clinical setting (12) versus based primarily on biologic differences] can be difficult, but becomes critical for developing a clinically useful breast cancer assay by this approach.
Data Processing
The massive amount of data created by microarray technologies fosters close collaboration between experimental biologists and statisticians. Commercial software (e.g., the GeneSpring Analysis Platform from Agilent Technologies) and open-source code (e.g., BioConductor, http://www.bioconductor. org) are available for analysis of genome-wide expression data. The open-source projects provide a wide range of powerful statistical and graphical methods for DNA microarray data analysis and promote high-quality documentation of the methods to facilitate reproducibility. Users thereby can apply the most up-to-date methods, without the worry of additional costs of add-on modules required with commercial software. However, scientists who want to engage in computational biology need to develop some programming skills. More user-friendly software freely available for academic users includes dChip (DNA-Chip Analyzer, http://biosun1. harvard.edu/complab/dchip/) and BRB ArrayTools (http://linus.nci.nih.gov/BRBArrayTools.html). FFPE breast  tumor tissue   KRT14  FOXC1  ID4  SFRP1  EGFR  KRT17  KRT5  FBP1  TM4SF13  COX6C  SLC39A6  TCEAL1  SCUBE22  KIAA1370  PIB5PA  PGR  ESR1  GATA3  BCL2  LRIG1  RABEP1  MYB  MLPH  CCND1   BC01249PE_UU  BC01032PE_UU  BC01210PE_UU  BC01056PE_UU  BC01339PE_UU  BC01023PE_UU  BC01063PE_UU  BC01406PE_UU  BC01362PE_UU  BC01186PE_UU  BC01452PE_UU  BC01266PE_UU  BC01300PE_UU  BC01435PE_UU  BC01384PE_UU  BC01257PE_UU  BC01373PE_UU Both spotted cDNA and high-density oligonucleotide array data are subject to variations during array manufacturing, RNA isolation, reverse transcription and labeling, sample hybridization, and image analysis; each of these can impact the gene measurements and create artifactual expression signatures. Normalization is a vital first step to minimize such variation, but different normalization methods can lead to different interpretations of the data. Spotted cDNA and oligonucleotide microarrays use one probe per gene and generate two channel measurements that assume the intensity of each probe is proportional to the amount of target; it is therefore essential to correct measurements by subtracting the background intensity in the spot region. A normalization method is then done within each array to eliminate systemic variations in dye biases (13) .
H&E
Because data analysis invariably compares results from multiple array experiments, a scaled normalization is carried out between arrays to adjust the distribution of logarithm intensity ratios to have a median of zero for each array. Most normalization methods are done by local regression (14, 15), although more sophisticated statistical methods (13, 16, 17) have also been proposed. The Affymetrix GeneChip employs multiple probes for each gene and a singlecolor detection method. Background intensity correction is also the first step (18, 19). Affymetrix GeneChip data can then be normalized across arrays, with various approaches available such as applying simple linear scaling in Affymetrix Microarray Suite software, nonlinear smooth curves using "rank invariant set" based on housekeeper control genes (20), and probe-level quantile normalization (19). As Affymetrix employs a set of several probes to represent one gene, summation of data is used to determine the corresponding mRNA quantities (19, 21) . Compared with spotted cDNA and oligonucleotide microarrays, high-density oligonucleotide microarray data processing is less intuitive to many experimental biologists, and choosing the most appropriate normalization methods can be challenging.
Presentation of Primary Data
Clearly issues such as normalization and the correct interpretation of these very large data sets are a subject of ongoing discussion. This is one major reason that the consensus among the microarray research community is that raw data supporting published studies should be made publicly available, allowing researchers to use their own techniques to mine data sets and compare studies. In 2001, the Microarray Gene Expression Data Society proposed experimental annotation standards, known as minimum information about a microarray experiment, and these standards are now supported by leading journals. Studies undertaken to compare data from different gene expression microarray platforms have found poor correlation between mRNA measurements from matched genes (22), and differences in data analysis approaches also create apparent poor correlations across platforms (23). However, recent large-scale studies have supported technical consistency across platforms and laboratories (24).
In breast cancer, concerns have been raised about the disappointingly small number of overlapping genes in different published gene expression predictors, leading to questions about the applicability of using microarrays as a platform for developing consistent assays of cancer biology. The most powerful method to confirm the relevance of a particular gene set is to determine how expression levels for that gene set predict outcome in samples analyzed at a different institution using a different platform. In response, an important study tested five published gene expression predictors of breast cancer prognosis (25)-the 70-gene profile (26, 27), activated wound response (28, 29), recurrence score (12), intrinsic biological subtypes (30-33), and two-gene ratio (34)-against a common set of 295 primary breast cancers (25). Results suggest that four of the five tested models show significant agreement in outcome predictions for individual patients.
Although some cancer microarray expression profile signatures fail to be confirmed, possibly because initial gene lists were developed using inadequate, purely internal training-validation designs (35), there are many that can be validated by comparisons with other gene array study sets or through complementary techniques such as tissue microarrays (TMAs). Below, these individual gene expression predictors are discussed in more detail. However, one very important conclusion that can be drawn is that public access to the primary data (e.g., Figure 1b ) not only makes that data set accessible for reanalysis with new bioinformatic tools, but perhaps even more importantly provides a data set useful for external validation studies of other signatures-the most critical step in discerning their potential clinical utility. Selected, large, publicly accessible repositories of breast cancer expression profiling data are shown in Table 1 .
Statistical Methods
After proper data processing and normalization, microarray expression profiling data are explored to seek biologically and clinically meaningful patterns. Bioinformaticians have developed many statistical methods to deduce gene expression predictors, which must be carefully applied to avoid problems. In primary analyses without an external validation set, there is a risk that genes found to be of interest in the initial set may not be significant in other samples, a phenomenon referred to as overfitting (36).
Older papers in the field often merely extracted the genes with the most extreme differences in expression or associations with clinical parameters, but global analyses of patterns within the data take much better advantage of the genome-wide scale of microarray data sets. Cluster analysis (37-40) is one of the most widely used multivariate methods employed in breast cancer gene expression studies to organize genomic-scale data. This method groups genes on the basis of their overall similarity in expression patterns across specimens, and tumor samples on the basis of their similarities in gene expression. Two popular clustering algorithms are hierarchical clustering and k-means clustering.
Hierarchical clustering (41) (42) (43) starts by assigning each subject as a cluster, each containing one subject. Then the closest and most (Figure 2f ). One weakness of hierarchical clustering is that small changes in the data can lead to quite different dendrogram relationships, and this kind of summary is valid only when the pair-wise dissimilarities between objects follow the hierarchical structure resulting from the algorithm (44, 45) . k-means clustering (46) attempts to segment N subjects into a predefined number of partitions. In brief, the operator first chooses the number of clusters, K. Then the algorithm randomly generates K clusters and computes the cluster centers in multidimensional space, known as centroids. Each subject is assigned to the nearest centroid, new centroids are computed, and these steps are iterated until convergence criteria are met (e.g., assignment of subjects does not change). The relative simplicity of this k-means algorithm is favored for its speed in handling large data sets. The disadvantage is that the initial selected number of clusters is somewhat arbitrary, and, if changed, cluster memberships change and may not be nested within the previously assigned clusters.
In 1998, Eisen et al. (47) implemented these procedures in a publicly available software known as Cluster, which allows experimental biologists with minimal knowledge of statistical programming to carry out these analyses. A Java-based software, Treeview (48) , was similarly made available to display the clustered profiles in a visually appealing manner, often referred as a heatmap. This graphical display is a useful tool for a twodimensional representation of the patterns of differential gene expression. The identification of breast cancer intrinsic biological subtypes (31, 33), discussed below, used these methods.
Unsupervised forms of data analysis such as hierarchical clustering permit discovery of inherent data patterns and relationships among genes and tumors, for example, highlighting the previously unrecognized basallike type of breast cancer (31). By comparison, supervised data analysis techniques identify genes whose expression most closely tracks with a known variable of interest such as tumor grade or patient outcome. An example of a result from supervised analysis is the 70-gene breast cancer prognostic signature (26), which linked tumor gene expression (among node-negative patients under age 55 with tumors less than 5 cm in size) to the presence or absence of distant metastases at 5 years.
The advantage of supervised approaches is that the extracted gene list will almost certainly link to the clinical question being addressed. The biggest disadvantage is that because gene selection is typically optimized against outcome from a set of patients with certain tumor characteristics and treatment regimens, the ability to generalize outside the patient set from which it is derived may be limited.
False discovery rates need to be quantified and limited to optimize gene lists (49) , for example, through the sophisticated semisupervised clustering and supervised principal component methods, proposed by Bair & Tibshirani (50) , using the nearest shrunken centroids. Such methods can serve, for example, as a method for developing a clinically practical customized mini-array or qRT-PCR assay sufficient to classify breast tumors into biological subtypes and to predict outcome. Other supervised microarray data analysis options include self-organizing maps (51) , support vector machines (52), artificial neural networks (53), Significance Analysis of Microarrays (54), and Gene Set Enrichment Analysis (55) . Regardless of the method chosen, for both unsupervised and, particularly, supervised approaches, results from genomic-scale experiments still need to be validated on independent series of tumors.
BREAST CANCER EXPRESSION PROFILES

Studies to Understand Breast Tumor Biology
The ability to measure concurrently the expression levels of tens of thousands of genes in cell lines and tumor specimens has, not surprisingly, expanded our understanding of the biology underlying breast cancer. The first published studies, from the Brown and Botstein labs at Stanford, showed that cDNA microarrays could identify expression signatures specific to breast cancer cells (56, 57) . A similar study showed that gene expression patterns can predict the invasive capacity of breast cancer cell lines (58) .
The first major published study on gene expression profiling of large numbers of clinically annotated breast tumor tissue specimens came out in 2000, wherein Perou et al.
(31) demonstrated a biological classification of breast cancers on the basis of distinctive patterns of gene expression. This study applied unsupervised hierarchical clustering to group 65 breast surgical excision specimens from 42 unique patients, using a condensed list of intrinsic genes. The intrinsic genes were defined as those showing significant variation in expression across different tumors but not between paired samples from the same tumor; this is one method to limit analysis to the subset of genes whose variation is more likely a product of biological differences between tumor specimens from different patients than of changes induced by individual patient or technical variability. These molecular interpretations, subsequently validated by studies from Sorlie et al. (32, 33) , correlated with patient outcome and, in addition to recognizing known clinically important subgroups, also indicated the existence of novel subtypes of breast carcinoma.
The five major biological breast cancer subtypes so derived are termed Luminal A, Luminal B, HER2 (human epidermal growth factor receptor 2 oncoprotein, product of the ERBB2 gene) overexpressing, basal-like, and normal-like; their variations in growth rate, specific signaling pathways, and cellular composition of tumors can be explained, at least in part, by their corresponding gene expression patterns. In particular, the proliferation genes are elevated in the three clinically aggressive subtypes: Luminal B, basal-like, and HER2 overexpressing breast cancers. In subsequent studies, these signatures have shown significant reproducibility in predicting patient survival in different cohorts of patients, by different laboratories using different gene array platforms and by novel unsupervised statistical methods (59) (60) (61) (62) .
One particularly important finding of this research was the highlighting and characterization of the basal-like subgroup of breast cancers, a biologically distinctive group for which targeted therapies are currently unavailable (63) . The existence of the novel subtype of basal breast carcinoma was confirmed not only by independent gene array studies but also by a series of immunohistochemical studies on TMAs containing breast carcinoma samples with known clinical features (64) (65) (66) . The intrinsic subtypes identified by gene expression profiling also correlate with genomic copy number aberrations identified by aCGH (67) .
Another interesting breast cancer gene expression pattern reflecting the underlying biology of cancer is the wound-response signature identified by Chang et al. (28, 29) , which supports the concept [proposed by H. F. Dvorak in 1986 (68) ] that a molecular program activated in normal wound healing is co-opted during cancer invasion and progression. This transcriptional signature is derived from cultured, serum-stimulated fibroblasts (29), and expression of this signature predicted poor clinical outcome among 295 early breast cancer tumors, improving the prediction of clinical outcome over that reflecting the risk stratification provided by clinical risk factors (28). The same signature also predicted poor outcome in gastric and lung carcinoma, indicating that the wound response is shared by a variety of tumor types and
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highlighting how investigations of breast cancer expression profiles have implications for other kinds of cancer. A similar approach was used to identify a hypoxia response signature from cultured mammary and renal tubular epithelial cells, and when present in breast cancer specimens, this gene signature is significantly associated with poor clinical outcome, independent of the wound healing signature and of standard clinical parameters (69) .
A recent study has proposed an "invasiveness" gene signature based on 186 genes, which includes apoptosis genes BCL2 and CASP8, chemotaxis genes PLP2 and CXCL2, and proliferation genes SSR1, EMP1, and ERBB4, selected because they are differentially expressed between tumor-derived CD44 + /CD24 − , highly tumorigenic breast cancer cells in comparison with reduction mammoplasty-derived normal breast epithelium cells (70) . This signature is designed to track a minority population of breast cancer cells that behave like stem cells in mouse xenograft assays (71) (72) (73) . The invasiveness gene signature shows strong association with clinical outcomes in breast cancers, consistent with the underlying idea that stem cells are present and important in breast cancer development (74, 75) .
Intriguingly, similar to the woundresponse signature mentioned above, this signature also has prognostic value when applied to other malignancies, including lung cancer, prostate cancer, and medulloblastoma data sets, suggesting it identifies a feature of general importance in cancer (70) . The invasiveness gene signature probably tracks a different process (more likely to reflect cancer stem cells) than the wound healing response (a nonoverlapping signature more directly linkable to local invasion). Combining these two results in even more impressive cancer risk stratification (70) , which can be interpreted as supporting the "seed and soil" hypothesis of cancer (76) .
Hereditary cases account for 5%-10% of breast cancers. BRCA1 and BRCA2 are the two susceptibility genes whose germ-line mutations are involved in most familial breast cancers, and their mutation status is reflected in somatic tumor gene expression profiles (32, 77) . A related gene array study compared BRCA1-mutated breast cancers with matched sporadic tumor specimens (78) , and reported that a subset of genes involving cell adhesion and migration such as laminins, different collagens, and fibronectins characterizes the BRCA1-associated tumors. Familial non-BRCA1/BRCA2-mutated breast cancers segregate into two distinct subclasses on the basis of gene expression profiling, and these two subclasses do not cluster together with BRCA1-or BRCA2-mutated familial cases (79) . These findings encourage the search for novel breast cancer predisposition genes among non-BRCA1/BRCA2-mutated familial breast cancer and should facilitate such studies, by allowing identification of similar cases within a heterogeneous background.
Studies to Improve the Diagnosis of Breast Cancer
Whereas gene expression profiling undoubtedly provides valuable biologic information to advance our understanding of breast cancer development and progression, its value as a clinical tool is less well proven. The diagnostic setting provides the most direct opportunity to translate gene expression information into clinical use. One relatively straightforward approach is to inspect the expression profile for biomarkers recognized by existing diagnostic immunohistochemistry antibodies. In this manner, for example, a simple immunohistochemistry panel was developed to identify the basal-like subtype of breast cancer (65) . Breast cancer gene expression profiles are maintained at sites of distant metastasis (80) , implying that such tests may even have some value in the setting of metastatic carcinoma of unknown primary sites.
Disrupted p53 function plays an important role in tumor progression and resistance to therapy (81) (82) (83) . However, conventional detection methods such as immunohistochemistry cannot reliably differentiate wild-type versus mutant versus deleted p53, leading to inconsistent and sometimes misleading research results. A 32-gene p53 signature, built from Affymetrix U133 expression profiles of 251 TP53-sequenced breast tumors, distinguishes p53-mutant from p53-wild-type tumors in multiple independent data sets, and does a better job predicting clinical outcome than mutation status (84) . The relevant p53 signature genes are not canonical targets of p53, but rather are associated with cell proliferation and growth, transcription, ion transport, and breast cancer biology. The signature thus reflects net changes in several cancer biology pathways induced by p53 dysregulation, a type of analysis for which expression profiling is better suited than other methods.
Gene expression profiling studies have also been linked to breast cancer histology. Invasive lobular carcinomas generally proliferate more slowly than ductal tumor, lose Ecadherin expression (85) , and are more often estrogen receptor (ER) and progesterone receptor (PR) positive (86) . They can show histological overlap with ductal carcinomas and are not always reliably distinguished in practice; perhaps because of this, invasive lobular and ductal carcinomas are treated similarly on the basis of stage, ER, and HER2 status.
Using spotted cDNA microarrays, a supervised analysis of 17 lobular versus 106 ductal breast cancers reported a signature of 11 genes (E-cadherin, survivin, cathespin B, TP11, SPRY1, SCYA14, TFAP2B, thrombospondin 4, osteopontin, HLA-G, and CHC1) to distinguish lobular and ductal subtypes (87) . This signature awaits external validation and clinical translation; a similar study found less clearcut differences between lobular and ductal carcinomas (88) .
Inflammatory breast cancer, in contrast, is easy to identify histologically and has underlying expression signatures that reflect the general biological subtypes seen in noninflammatory cases (89, 90) . Using an 18,000 feature cDNA array from the Netherlands Cancer Institute, Hannemann et al. (91) recently presented publicly available data from a comparison of forty cases of ductal carcinoma in situ with an equal number of invasive breast cancers. The authors present a classifier of 35 genes that could stably distinguish between groups with 91% accuracy, among which transforming growth factor-β2 and matrix metalloproteinase 11 were prominent members. The authors further described a classifier that distinguishes well-differentiated from poorly differentiated ductal carcinoma in situ. These findings were validated by internal statistical methods, but again await external validation and clinical translation.
Returning to the topic of hereditary breast cancer, the current diagnostic test for BRCA1/BRCA2 mutation is time and labor intensive. Given that subtle changes at the DNA level may induce more profound and widespread changes at the RNA level, gene expression profiling offers a potential alternative to identifying mutation carriers. Indeed, not only do the hereditary breast tumors themselves bear characteristic expression signatures (77-79), non-neoplastic fibroblasts from BRCA1 and BRCA2 mutation carriers also present distinct gene expression signatures after radiation-induced damage, consistent with an altered DNA repair response (92) . If validated, this information could be used to create a screening test based on the net functional defect in these patients, which cannot always be inferred even from sequencing. (97) results, which demonstrated that proliferation gene expression signatures are most powerfully prognostic among older, ERpositive patients. Although pathologists can assess proliferation activity by mitotic counts and/or Ki67 immunohistochemistry, fixation issues and variability in visual counting methods probably explain why a gene expression panel seems to do a significantly better job at this task. For the moment, histological grading is so cheap and convenient that it will be hard to replace even by better measurements. However, if gene expression profiling in some form becomes more clinically accessible, proliferation signatures appear poised to be an important application in breast cancer analysis.
Studies to Identify Prognostic Signatures
The 70-gene prognostic signature, identified from the Netherlands Cancer Institute primary breast cancer cases (26, 27), is an excellent example of applying supervised learning on gene expression profiles. This signature, showing prognostic value for distant metastasis within five years, was first identified using a cohort of 78 node-negative breast cancers occurring in women below age 55 who had not received systemic adjuvant therapy, using oligonucleotide microarrays (26). Many genes involving the hallmarks of cancer are represented: cell cycle, metastasis, angiogenesis, and invasion. This prognostic profile was then validated on a cohort of 295 young patients from the same institution, including node-positive and node-negative tumors with and without systemic treatment (27).
The prognostic value of the 70-gene signature was significantly better at predicting distant relapse-free survival than standard St. Gallen or National Institutes of Health clinical criteria. As this study included the original data set used to derive the prognostic value in its initial validation, a concern of possible data overfitting has generated debate in the microarray community (36), and it remains unclear if this signature really does perform better than the Nottingham prognostic index (98) . Nevertheless, the authors of this study made their primary data publicly accessible, making this data set a particularly valuable resource for validation and comparative studies by others in the field (25, 28, 35, 69, 99, 100). A Danish group confirmed the prognostic value of the 70-gene signature in low-risk primary breast cancers, but presented a 32-gene classifier that appeared to be better among the very lowest-risk subset (101), a result that requires external validation.
The 76-gene Rotterdam signature, identified by Wang et al. (102) using Affymetrix U133A arrays on a set of 115 breast cancer patients, was developed to predict distant relapse rate in untreated node-negative patients. This classification algorithm was trained and optimized in ER-negative and ER-positive patients separately, on the basis of the assumption that the mechanisms driving these two types of cancers are distinct. The genes forming the signature are involved mainly in DNA replication and repair, cell cycle and apoptosis, and immune response. The prognostic value of this 76-gene signature has been validated on an independent set of 180 nodenegative untreated patients from different institutions (103) and is also available for public access.
Analysis of the particular genes expressed in a primary breast tumor may also be able to classify the risks for site of distant metastasis. The 70-gene and intrinsic subtype signatures have been shown to be preserved between primary and metastatic sites, supporting the idea that metastatic capacity is inherent in the primary tumor and that metastases closely reflect the biology of the primary tumor (80) . Gene signatures that predict breast cancer metastasis to bone (104) and lung (105) have been published. Predicting risk of bone metastasis, in particular, could guide imaging follow-up (e.g., need for bone scans) and/or use of adjuvant bisphosphonates (104) .
Prognostic models suffer from inherent limitations. In general, different patient populations and statistical methods will yield different optimal prognostic signatures (106, 107) . Supervised analyses optimized against outcome will necessarily be overfitted to the data set from which they are derived and will be expected to lose some prognostic power in validation studies on other data sets. Gene lists need not be expected to overlap, as distinct genes may track similar biological processes (25). Finally, no matter how sophisticated and thorough a microarray analysis may be, there is a stochastic component to patient outcome that will prevent any prognostic model from being perfect-there is a certain unavoidable randomness to fate.
Studies to Predict Tumor Response to Adjuvant Systemic Therapy
The major clinical goal in applying gene expression profiling to breast cancers is to guide more individualized neoadjuvant or adjuvant systemic therapies; conventional biomarkers other than ER and HER2 have not been able to help greatly in this regard. Thus, many studies have sought to use microarray expression profiling to go beyond prognostic signatures to develop predictors of drug response.
Expression profiling of cell cultures before and after drug treatment can be used to develop drug response predictors that may be applied to patient tumor specimens. Doxorubicin-and 5-fluorouracil-induced changes in gene expression seen in cell lines are also seen in tumor specimens from treated patients (108) . Cells with luminal-type expression profiles responded by inducing cell cycle checkpoint genes not induced by cells with a basal-like expression profile, indicating that the intrinsic biologic subtype could influence tumor response to conventional chemotherapy. Using various chemotherapysensitive carcinoma cell lines as models, a 79-gene doxorubicin resistance signature (including the P-glycoprotein efflux pump) was identified using 43,000 spot cDNA microarrays (109) . This signature could be identified in publicly available primary breast cancer specimens and correlated with shorter patient survival, although it has yet to be validated in clinical material randomized to anthracycline versus nonanthracycline therapy.
Treatment of cell cultures with estrogens has also been used to identify an estrogen response signature, including PR, RERG, CTSD, and PDZ1 and proliferationassociated genes such as CCNB2, CCND1, MKI67, MYBL2, BIRC5 (survivin), and STK6 (110) . When applied retrospectively to multiple independent breast cancer expression profile data sets, this 822-gene classifier predicts outcome among ER-positive and tamoxifentreated patients.
In the absence of long-term follow-up data, complete pathological response is used as a surrogate end point for patient benefit in a neoadjuvant setting, and exploratory microarray analyses have been incorporated into some clinical trial designs. A study using Affymetrix HgU95-Av2 arrays to compare expression profiles before and after neoadjuvant docetaxel reported that sensitive tumors have higher expression of genes involved in cell cycle, cytoskeleton, adhesion and protein transport, and modification (111), whereas resistant tumors express the mammalian target of rapamycin (mTOR) survival pathway. This small study (N = 13) requires confirmation, and the implication that mTOR inhibitors may make an effective combination therapy needs experimental validation.
In contrast, Hanneman et al. (112) were unable to generate expression predictors of pathologic response in 24 doxorubicincyclophosphamide and 24 doxorubicindocetaxel neoadjuvant breast cancer patients (T > 3 cm and/or node positive) using 18,000 spot cDNA microarrays. A 31,000 cDNA microarray study of 42 patients (24 for classifier discovery and 18 for validation) yielded a 74-gene classifier to predict complete pathologic response to paclitaxelfluorouracil-doxorubicin-cyclophosphamide (T/FAC) neoadjuvant chemotherapy (113) . In this case, the training-validation split was a very appropriate design method, but left small numbers of events in each group, yielding validation results with borderline significance and low sensitivity (i.e., the study correctly predicted three of seven patients who did respond and eleven of eleven who did not).
Expression profiles from 37 locally advanced patients treated with neoadjuvant liposomal doxorubicin-paclitaxel chemotherapy were evaluated using U133 Plus 2.0 microarrays (114) and linked to outcome. No strong link was possible to clinical or primary site pathologic response in the primary tumor, although a gene list predicting nodal involvement at subsequent surgery was generated that had general prognostic value in univariate analyses in two other series.
For future studies, valuable, prospectively collected before-and-after neoadjuvant samples may best be used to validate preexisting hypotheses about gene predictors, rather than be sacrificed to deduce lists of novel predictor genes (an analysis that can and should still be performed secondarily from the data generated on such specimens). For example, in a study of 82 patients treated with neoadjuvant T/FAC profiled using U133A microarrays, pathologic complete response (pCR) was much higher in cases expressing the previously established basal-like and HER2-positive intrinsic subtype signatures (both with 45% pCR) than in tumors with luminal (2 of 30 pCR) or normal-like (0 of 10 pCR) expression profiles (115) . Exploratory gene lists correlating with pCR were then generated by supervised analyses and, interestingly, are completely different between the basal-like and HER2 types, suggesting that tumors with different intrinsic biology employ different mechanisms of drug resistance.
One unanswered question is whether molecular profiles outperform available clinical and pathological parameters. A 28K cDNA microarray study showed gene expression profiles perform as well as (but no better than) classifiers based on clinical parameters and the Nottingham prognostic index to predict odds of recurrences in a cohort of 85 premenopausal, lymph-node-positive breast cancer patients treated with adjuvant CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) (116) . This group of patients generally receives aggressive treatment, and the potential to identify any who could be spared chemotherapy would be clinically relevant.
ER-positive tumors are typically associated with better clinical outcomes and good response to hormonal therapies such as tamoxifen (117) . However, a subset of patients recurs, and up to 40% develop resistance to tamoxifen (118) . Results from randomized trials suggest that aromatase inhibitors can reduce the recurrence risk, especially at distant sites, for postmenopausal endocrine-responsive breast cancers (119) (120) (121) (122) . Response to such endocrine therapies can be correlated with global gene expression patterns among ER-positive breast cancers.
Using 18,000 cDNA microarrays, Jansen et al. (123) profiled 10-to 20-year-old frozen primary tumor specimens from patients who received adjuvant tamoxifen. They identified an 81-gene signature (26% involving estrogen action, 14% apoptosis, 9% extracellular matrix formation, and 6% immune response), discriminating 21 patients with objective response from 25 with progressive disease. This list was further reduced to a 44-gene optimal predictive signature and validated on a separate set of 66 breast tumors, confirming significant predictive value for longer time to progression. The overall accuracy to classify tamoxifen resistance was 80%.
A similar study by Ma et al. (34) used 20,000 oligonucleotide microarrays to profile 60 frozen primary tumor samples from women treated with adjuvant tamoxifen, from which they distilled a two-gene ratio predictor for tamoxifen resistance. The genes, HOXB13 and IL17BR, did not have any previously characterized functional relevance to tamoxifen resistance. Initial validation was performed on 20 independent cases by qRT-PCR, which can be readily applied to formalin-fixed tissue. Subsequent validation studies found this ratio to be predictive only among nodenegative breast tumors (124) , and independent groups have not been able to verify strong concordance with other expressionprofile-derived predictors (intrinsic subtype, 70-gene Amsterdam, wound healing, and recurrence score signatures) (25).
Standard pathology blocks of formalinfixed, paraffin-embedded tissue are more amenable to qRT-PCR (Figure 2) A later report evaluated the performance of this assay in 651 ER-positive and nodenegative breast tumors, which as part of NSABP B20 had been randomized to tamoxifen or to tamoxifen plus chemotherapy (125) . Patients with high recurrence scores had a large benefit from chemotherapy (0.26 relative risk and 27.6% mean absolute decrease in a 10-year distant recurrence rate), whereas the low recurrence score group (54% of patients) derived essentially no benefit. On the basis of these exciting results, this assay was promptly offered as a commercial test (Oncotype Dx TM ). Controversy remains, however, as the 651 patient set included 227 cases from the tamoxifen arm of NSABP B20, data which were used during the model development phase and then reapplied to the larger combined data set, making the prediction of benefit from chemotherapy appear more impressive (126) . As with other commercially available tests (such as MammaPrint), it also remains unclear whether it provides a cost-effective advance www.annualreviews.org • Breast Cancer Expression Profilingover standard clinicopathologic factors routinely being obtained on all patients.
Predictive assays are in high demand to drive clinical care decisions. Ultimately, proof of the clinical value of expression signatures will require prospective clinical trials, ideally with decision making randomized as to whether decisions are based on standard clinicopathological factors or on the information derived from expression profile signatures. Prospective trials assessing the 70-gene Amsterdam signature and 21-gene recurrence score assays are now underway to help address these issues (described further below).
Studies to Identify Therapeutic Targets
Previous technologies used to analyze broad aspects of tumor biology, such as histomorphology and chromosomal karyotyping, do not directly provide information about drug sensitivity. Microarrays not only identify broad gene expression patterns important to tumor biology, but also link these patterns to specific genes that may be targeted by established or experimental drugs. The re-identification of ESR1 (encoding ER) and ERBB2 (encoding HER2) as central genes within identifiable subtypes of breast cancer, as defined by microarray expression profiling, serves as a validation of this technology as a means to identifying relevant drug targets (31). The basal-like molecular phenotype expresses neither ER nor HER2, but does characteristically overexpress epidermal growth factor receptor (32, 33, 56, 65), which is targeted by several new drugs used in colorectal, head and neck, and lung carcinomas, one of which (erlotinib) showed activity in a breast cancer pilot trial (127) .
An early study using spotted membranebased arrays to screen 124 genes on 18 breast tumors highlighted ESR1 and HSP90 as top targets (128) . Studies now use microarrays measuring in excess of 40,000 transcripts, in over 100 specimens at a time; one more recent study that combined expression profiles with genomic aCGH expression profile data highlighted ERBB2, FGFR1, IKBKB, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1 as top targets that are potentially druggable with available agents (67) . Other studies have proposed matrix metalloproteinases (129) or NFκB (130) as key targets, in particular breast cancer histologic subtypes. One potentially exciting finding is that apparent estrogen independence and tamoxifen resistance may be conferred, in some cases, by upregulation of androgen receptor action (131, 132) , suggesting there would be resistance to aromatase inhibitors but sensitivity to anti-androgens in these patients. Such findings highlight the ability of gene expression profiling to identify pathways that, although only relevant in a minority of breast cancer patients, can be targeted by existing drugs, facilitating the development of personalized medicine.
However, it is important to realize that gene expression, particularly in a microarray study, does not necessarily correlate with the identification of a useful therapeutic target ( Table 2) . Experimental validation, including typical in vitro drug sensitivity assays, is a necessary step even when a target of a wellestablished drug appears to be expressed in breast cancer specimens. Expression profiling is only a discovery-based screen, albeit a marvelously comprehensive one, for drug targets.
CHALLENGES AND FUTURE DIRECTIONS Potential Limitations of Breast-Cancer-Profiling Studies
The emergence of prognostic (associated with clinical outcome) and predictive (associated with response to therapy) gene expression signatures holds promise for attempts to individualize breast cancer treatment; however, some studies have raised concerns about the clinical applicability of these published signatures. One concern was that the 76-gene signature, identified by Wang et al. (102) to predict distinct metastasis in untreated nodenegative patients of all age groups shared only three genes with the 70-gene signature developed by the Amsterdam group (van't Veer, van de Vijver and colleagues) to predict a fiveyear distant metastasis risk for node-negative patients younger than 55 years of age (26, 27). This cannot be explained simply by the use of different microarray platforms (the Affymetrix and Agilent platforms share large numbers of overlapping features, particularly for characterized genes important in cancer) nor by the partial differences in patient selection criteria.
Rather, it appears that in breast cancer, multiple distinct gene sets, derived through a variety of approaches and perhaps representing distinct biological processes, can result in prognostic models with a high degree of significance. Thus, although there may seem to be little consistency between studies in the actual gene lists, a recent report comparing five independent published breast cancer gene signatures (25) validated four of them as correlating equally well with survival when applied to one common primary microarray data set (26-28). The four gene signatures showing significant agreement in outcome predictions are the 70-gene Amsterdam signature, woundhealing response, 21-gene qRT-PCR recurrence score, and intrinsic molecular subtype signatures. This important finding implies that, despite differences in gene lists, these separate signatures may contribute equally to the prognostic space in breast cancer (133) . Only the two-gene ratio (HOXB13:IL17BR) failed to show prognostic value in this study, a result also found by others (134) .
In a separate approach to devise more robust gene signatures, one study suggested that combining cross-platform microarray data sets (135, 136) into one single data set may yield gene signatures with a higher predictive power that may be more broadly generalized (137) . This finding emphasizes, again, how valuable it is to make primary microarray raw data publicly accessible, to allow external validation, optimization, and meta-analysis studies. There can be a selection bias in extracting significant genes from among thousands of measurements (138) , suggesting a need to estimate an error rate by cross-validation or bootstrapping during the gene-selection process. Using the same data set from which the 70-gene signature was originally derived (26), an independent group demonstrated that many predictive gene lists can be selected that correlate equally well with survival, but the correlation fluctuates when measured over different subsets of patients (100). This observation is shared by another study reporting that, using the same data set, the performance of molecular gene signatures can be unstable and depends upon the selection of patient subsets in creating the training sets (35).
After an initial burst of descriptive publications on breast cancer profiles, studies such as these have already become increasingly important, and elements of external validation and data accessibility are now obligatory for publication of gene expression profiling studies in major journals. A recent study, designed to assess the value of a mathematical method named Probably Approximately Correct to quantify the stability of gene signatures, reported that gene expression profiles from thousands of breast cancers may be needed during the discovery phase to deduce a truly definitive predictive list of genes that can have an overlap with more than 50% in a second list of genes derived from similar specimens (139) . Discovery-based expression profiling studies on this scale will be almost impossible to realize. Nevertheless, it should be kept in mind that the original 70-gene signature, like several other signatures mentioned above, has now been shown to be a significant prognosticator independent of traditional prognostic markers in a variety of retrospective validation sets.
Concerning the issue of technical consistency across platforms, the intrinsic subtypes model, for example, has been validated to show consistent class assignments across three microarray platforms-Applied Biosystems 60-mer oligonucleotide microarrays, Stanford cDNA microarrays, and Agilent 60-mer oligonucleotide microarrays (140)-and further validated against qRT-PCR for a minimal subset of discriminator genes. Furthermore, the basal subtype of carcinoma recognized using these expression profiling platforms has been validated using immunohistochemistry on TMAs (as further discussed below).
Contribution of Noncancerous Elements to Breast Cancer Expression Profiles
Tumor specimens consist of a complex mixture of invading malignant epithelial cells and their surrounding stroma containing fibroblasts, myofibroblasts, endothelial cells, fat, mast cells, and inflammatory cells. In addition, the samples used for gene array studies may contain normal breast tissue or in situ carcinoma. A fundamental limitation of expression profiling is the correct attribution of the gene expression measurements to the cancer cells themselves. Although laborious, and therefore necessarily reducing sample throughput, this issue can be addressed by laser microdissection (60, 141, 142) or similar techniques. Allinen et al. (143) used a magnetic beadbased cell sorting coupled with serial analysis of gene expression to determine the transcriptional profile of stromal and epithelial cells in normal breast, in situ, and invasive breast carcinoma. At a minimum, frozen sections of the tumor tissue used for RNA isolation should be cut and examined by a pathologist to confirm that the sample is correctly diagnosed and representative of the tumor, as well as to determine the percentage of cancer cells.
To a certain extent, the signature contributions of stroma, normal epithelium, and inflammatory cells can be picked out by bioinformatics, but many genes may function differently in different cells and thus wholesale subtraction of such genes is probably inappropriate. In addition, the non-neoplastic elements adjacent to cancer have distinct, abnormal signatures (60) of their own. Stromal signatures in breast cancer can be matched to soft tissue tumor signatures (99) : In a proofof-principle study using expression profiles of two soft tissue tumors, it was shown that stroma in aggressive breast cancers resembles the solitary fibrous tumor signature (similar to epithelial support fibroblasts), whereas stroma in less-aggressive tumors express a fibromatosis-like signature [similar to scar and seen in normal breast stroma as well (60)].
Note that contributions by non-neoplastic stromal elements are still very important to overall tumor biology and clearly can relate to prognosis (144) . However, if the expression data are being mined for diagnostic markers or therapeutic targets, genes expressed in stromal cells will not be as disease specific. Although drugs targeting a stromal cell gene might be more likely to have side effects on normal tissues, such agents may also prove particularly effective inasmuch as the target cell lacks a cancer cell population's capacity to rapidly acquire resistant mutations. Moreover, the stromal reaction signatures seen in breast carcinoma may be shared at least in part with other carcinoma types, and thus could lead to the development of drug targets that could be effective in a variety of epithelial malignancies.
Given the issues with ascribing gene expression profiles derived from a complex mixture of cells to individual cell types within the specimen, TMA technology (145) has become a valuable tool for high-throughput validation of expression profiles with morphologic correlation (146) .
TMAs are constructed by transferring small cores of paraffin-embedded tissue samples to a recipient block, which allows the assessment of one biomarker's expression across hundreds of patients in one experiment. This has the advantage of allowing access to large banks of existing tumor samples independent of those used for expression profiling, which may already be linkable to mature patient outcome data. The main limitation is the capacity to validate only one gene at a time, and TMA-based analyses are really limited to techniques applicable on formalin-fixed, paraffin-embedded tissue (primarily protein-level analysis by immunohistochemistry, and mRNA and DNA analysis by in situ hybridization).
Using TMAs linked to clinical outcome, surrogate immunohistochemical panels can be developed in an attempt to recapitulate the biological subgroupings of breast cancer derived from full gene expression profiles. The basal-like intrinsic subtype can be identified using a panel of established immunostains recognizing ER, PR, HER2, epidermal growth factor receptor, and cytokeratin 5/6 (Figure 3) (65) . This panel remained prognostic on an independent cohort of patients, and by allowing assessment of standard pathology blocks, the basal-like breast cancer subtype was especially prevalent among premenopausal African American patients (147) . Immunohistochemical surrogate panel derived from gene expression profile data allows molecular subtyping of breast cancers on tissue microarrays.
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Novel prognostic immunostaining panels can also be identified by using TMAs (148) . The objective of MINDACT is to assess prospectively whether 10%-15% of lowrisk breast cancer patients can be spared from adjuvant chemotherapy, on the basis of results obtained with the MammaPrint microarray (152). As this expression signature, which requires fresh tissue, could not first be applied to retrospective studies with treatment and outcome information, this is a necessary, bold step to carry such a gene expression signature forward into a phase III trial. Unlike in the TAILORx trial, wherein all patients are to receive the molecular test, patients in MINDACT will be randomized as to whether they receive the test or not, providing a particularly rigorous assessment as to whether the expression profile improves treatment decisions over current gold standard methods.
Gene Predictors as Diagnostic Tests for Clinical Use
CONCLUSIONS
Gene expression profiling analysis is a fastmoving field, with new and improved platforms and data analysis methods coming out on almost a monthly basis. General principles that have emerged include the value of public access to primary data and the need for external validation studies, lessons that should also be applied to other high-throughput techniques such as aCGH and proteomics studies. Multiple gene expression signatures relating to breast cancer biology, diagnosis, prognosis, and prediction have been described, and the technique has excellent potential as a discovery tool for new therapies. With some modifications, this technology is being applied to clinical specimens, and commercially available tests have been released. Such tests are being assessed in prospective trials, whose findings will not be available for several years. Nevertheless, gene expression profiling studies of breast cancer are to a large extent more advanced than those in other solid tumor types and are providing important information about how expression profiling technology can be used to help patients with cancer.
SUMMARY POINTS
1. Several technical platforms and statistical methods for generating and analyzing gene expression profiles exist, and the field continues to develop rapidly.
2. Public availability of primary microarray data in an accessible format is vital not only to allow alternative data analysis tools to be applied, but also to provide data sets for external validation studies.
3. Gene expression signatures relating to breast cancer biology, diagnosis, prognosis, and response to treatment have been published, several of which have been validated in independent series.
4. Large prospective clinical trials are now underway to assess the value of gene expression profiles for clinical decision making in breast cancer.
5. Lessons learned about study design and insights gained about the biology of breast cancer are relevant to other tumor types.
FUTURE ISSUES
1. External validation should be rigorously pursued to assess the clinical importance of particular signatures, and neoadjuvant studies in particular should include planned attempts to validate published predictive signatures, in addition to exploratory research to discover new signatures.
2. Proof that expression profiling technologies can contribute to the cost-effective improvement in patient care decision making over standard clinicopathologic methods will be required for such expression profiling technologies to achieve widespread clinical use.
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